Eisai and Biogen Idec pool Alzheimer's efforts
This article was originally published in Scrip
Eisai and Biogen Idec have entered into a collaboration to develop and commercialize two of Eisai's clinical pipeline candidates for Alzheimer's disease, E2609 and BAN2401. The agreement also gives Eisai an option to jointly develop and commercialize two of Biogen Idec's candidates for Alzheimer’s disease, the anti-amyloid beta (Aβ) antibody BIIB037 and an anti-tau monoclonal antibody.
You may also be interested in...
Multiple competitors have ended development of BACE inhibitors for the treatment of Alzheimer's disease, but Eisai neurology executive Lynn Kramer tells Scrip that the company still sees a path forward for certain amyloid-targeting drugs.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.